Omega Healthcare Investors, Inc. — FY2022 Form 10-K Summary
Business context and reporting period
Omega is a healthcare real estate investment trust structured as an UPREIT. It owns, finances and leases primarily skilled nursing facilities and assisted living facilities in the U.S. and U.K. The filing covers the fiscal year ended December 31, 2022, with comparative information for 2021 and 2020. Omega reported one operating segment.
- Portfolio: 926 healthcare facilities in 42 states and the U.K., operated by 67 third-party operators.
- Property mix: 664 leased SNFs, 169 ALFs, 20 ILFs, 16 specialty facilities, two medical office buildings, mortgage investments in 52 facilities, six unconsolidated joint ventures and two facilities held for sale.
- Total investments were $10.3 billion at year-end, compared with $10.7 billion in 2021. Net real estate investments were $7.8 billion.
Financial performance and key metrics
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Total revenues | $878.2 million | $1,062.8 million | Down $184.6 million |
| Rental income | $750.2 million | $923.7 million | Down $173.5 million |
| Interest income | $123.9 million | $136.4 million | Down $12.5 million |
| Net income | $438.8 million | $428.3 million | Up $10.5 million |
| Net income available to common stockholders | $426.9 million | $416.7 million | Up $10.2 million |
| Basic/diluted EPS | $1.81/$1.80 | $1.76/$1.75 | Increased |
| Nareit FFO | $460.5 million | $655.2 million | Down $194.7 million |
| Net cash from operating activities | $625.7 million | $722.1 million | Down $96.4 million |
- Net margin was approximately 50.0% in 2022 versus 40.3% in 2021, but reported net income benefited materially from a $360.0 million gain on asset sales. Nareit FFO, which excludes most real estate disposition gains, declined substantially.
- Expenses totaled $799.7 million, including $332.4 million of depreciation and amortization, $68.7 million of credit-loss provisions, $38.5 million of real estate impairments and $42.0 million of acquisition, merger and transition costs.
- Allowance for credit losses increased to $188.4 million from $144.5 million at year-end 2021.
- Cash, cash equivalents and restricted cash totaled $300.6 million, up from $24.4 million. Cash flow benefited from $759.0 million of net proceeds from real estate sales.
- Quarterly dividends totaled $2.68 per share, and the Board declared a further $0.67 per-share dividend payable in February 2023.
Debt, liquidity and capital resources
- Total debt was approximately $5.3 billion, representing 58.4% of total capitalization. The weighted-average interest rate was 4.1%, and 98% of debt with outstanding principal had fixed interest payments.
- Debt consisted principally of $4.9 billion of senior unsecured notes, $366.6 million of secured borrowings and $19.2 million drawn on the $1.45 billion revolving credit facility.
- Near-term scheduled principal maturities included $359.9 million in 2023, $427.7 million in 2024 and $477.5 million in 2025. Total contractual debt, interest and operating obligations were $6.6 billion.
- Credit ratings were Baa3 from Moody’s and BBB- from S&P Global and Fitch. Omega reported compliance with all debt covenants.
- Remaining liquidity included $929.9 million of capacity under the 2021 ATM equity program, although the company did not use the ATM program in 2022. Omega repurchased 5.2 million shares for $142.3 million during the year.
- Additional commitments totaled $282.3 million, including $203.7 million of construction and capital commitments and $71.4 million of non-real-estate loan commitments.
Material changes versus the prior comparable period
- Revenue declined primarily because of cash-basis accounting and write-offs related to operators with collectibility problems, reduced payments from distressed operators, facility sales and transitions.
- Omega placed nine additional operators on a cash basis during 2022 and had 20 operators on a cash basis at year-end. These operators represented 36.5% of 2022 revenue excluding write-offs.
- Omega recorded $119.8 million of straight-line receivable and lease-inducement write-offs in 2022 versus $36.0 million in 2021.
- Omega sold 66 facilities for approximately $759.0 million of net proceeds and recognized a $360.0 million net gain, compared with 48 facilities sold and a $161.6 million gain in 2021.
- Acquisitions fell to $225.2 million for 41 facilities from $604.0 million in 2021. Capital improvement and construction investment declined to $64.4 million from $140.0 million.
- FFO declined 30% and operating cash flow declined 13%, despite higher GAAP net income, reflecting weaker recurring rental and interest collections.
Guidance, outlook, commentary and risks
- Management did not provide a clear numerical earnings or FFO outlook in the filing. It expects near-term uncertainty to persist and remains cautious regarding operator liquidity, occupancy recovery and government support.
- COVID-19 effects continued through staffing shortages, elevated agency labor and overtime costs, lower occupancy, increased infection-control expenses and delayed admissions. The federal public health emergency was scheduled to end May 11, 2023, with related reimbursement and Medicaid support phasing down.
- Management expects continued opportunistic sales or transitions of underperforming and non-strategic assets. Long-term demographic trends are viewed favorably, but the timing of occupancy and labor-market recovery remains uncertain.
- Significant operator restructurings involved Agemo, Guardian, LaVie, Maplewood and other operators. These included rent deferrals, reduced contractual payments, loan modifications, non-accrual accounting, use of security deposits and letters of credit, and facility sales or transitions.
- LaVie was placed on a cash basis in the fourth quarter, generating approximately $58.0 million of write-offs. Maplewood was also placed on a cash basis, generating approximately $29.3 million of write-offs. Further LaVie restructuring activity was expected in 2023.
- Key risks include operator bankruptcy or nonpayment, Medicare and Medicaid reimbursement reductions, labor inflation, occupancy weakness, interest rates, refinancing needs, impairment and credit losses, geographic and operator concentration, regulatory enforcement, REIT qualification and limited liquidity in healthcare real estate.
- Geographic concentration was highest in Florida at 11.5% of investments, Texas at 10.3% and Indiana at 6.6%. Maplewood was the only operator representing more than 10% of total investments at year-end.
- The company recorded a $31 million reserve for a securities class-action settlement, offset by an insurance receivable. The settlement was subject to final court approval as of the filing date. Omega also paid approximately $3.1 million in 2022 to settle a DOJ-related Lakeway investigation, with no remaining reserve reported for that matter.
Most important facts for investors to verify
- Whether occupancy, staffing costs and operator coverage ratios improved after the COVID-19 public-health-emergency support began to phase out.
- The collectibility and restructuring status of LaVie, Maplewood, Agemo, Guardian and other cash-basis operators, including the adequacy of collateral and credit-loss reserves.
- Recurring FFO and operating cash flow excluding asset-sale gains, write-offs, security-deposit applications and other unusual items.
- Refinancing plans and available liquidity for the $359.9 million of 2023 maturities and subsequent debt maturities.
- Whether the $282.3 million of construction, capital-improvement and loan commitments will be funded and whether additional operator support will be required.
- The final outcome of the securities class-action settlement and the pending Gulf Coast subordinated-debt litigation.
- Continued compliance with debt covenants, credit ratings and the requirements to maintain REIT status and dividend distributions.